Dashboard
Manage Tickers

GNTA Genenta Science S.p.A.

Nasdaq genenta.com


$ 3.21 $ -0.03 (-1.03 %)    

Thursday, 16-Oct-2025 13:24:05 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 3.1768
$ 3.26
$ 2.80 x 1
$ 3.51 x 1
$ 3.17 - $ 3.38
$ 2.56 - $ 6.12
2,218
na
58.1M
$ 0.17
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
07/02/2025 12:06:54

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/01/2025 12:07:35

genenta-reports-emerging-survival-signals-in-gbm-study-2-year-survival-doubles-vs-historical-data-no-new-safety-concerns-with-temferon
Genenta Reports Emerging Survival Signals ...
07/01/2025 09:15:56

genenta-science-collaborates-with-anemocyte-for-manufacturing-critical-starting-materials-for-cutting-edge-cell-based-therapies
Genenta Science Collaborates With Anemocyt...
05/07/2025 11:06:33

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collabor...

genenta-science-secures-219m-funding-via-mandatory-convertible-bond-from-enea-tech-to-advance-temferon-in-metastatic-renal-cell-cancer
Genenta Science Secures $21.9M Funding Via...
03/19/2025 13:31:39

Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 mill...

genenta-science-has-amended-its-partnership-with-agc-biologics-and-introduced-an-exclusive-gmp-suite-at-the-agc-biologics-cell-and-gene-center-of-excellence-in-milan-to-manufacture-genentas-cell-therapy-product
Genenta Science Has Amended Its Partnershi...
01/09/2025 11:02:29

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
10/11/2024 16:31:16

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
10/10/2024 16:31:42

hc-wainwright--co-reiterates-buy-on-genenta-science-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on Gene...
10/02/2024 14:41:11

HC Wainwright & Co. analyst Joseph Pantginis reiterates Genenta Science (NASDAQ:GNTA) with a Buy and maintains $25 price...

the-agenzia-italiana-del-farmaco-has-approved-genenta-sciences-new-phase-1-trial-for-metastatic-renal-cell-cancer-for-genentas-flagship-product-temferon
The Agenzia Italiana del Farmaco Has Appro...
10/02/2024 10:33:24

hc-wainwright--co-reiterates-buy-on-genenta-science-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on Gene...
05/13/2024 09:51:51

HC Wainwright & Co. analyst Joseph Pantginis reiterates Genenta Science (NASDAQ:GNTA) with a Buy and maintains $25 price...

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
02/12/2024 17:31:18

genenta-science-has-dosed-first-of-three-patients-in-cohort-8-temferon-at-4x106kg-the-last-cohort-of-phase-1-dose-ranging-part-of-phase-12-trial-in-newly-diagnosed-umgmt-glioblastoma-multiforme-patients-top-line-data-expected-by-end-of-2q24
Genenta Science Has Dosed First Of Three P...
02/08/2024 10:03:38

why-urban-outfitters-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Urban Outfitters Shares Are Trading Lo...
11/22/2023 19:03:09

Shares of Urban Outfitters, Inc. (NASDAQ: URBN) dipped during Wednesday’s session after the company reported third-quarter fina...

genenta-announces-ongoing-clinical-trial-progress-and-proposed-expansion-in-solid-tumor-treatments
Genenta Announces Ongoing Clinical Trial P...
07/28/2023 07:21:02

roth-mkm-assumes-genenta-science-at-buy-announces-price-target-of-15
Roth MKM Assumes Genenta Science at Buy, A...
06/29/2023 13:21:28

Roth MKM analyst Kumaraguru Raja assumes Genenta Science (NASDAQ:GNTA) with a Buy rating and announces Price Target of $15.

genenta-science-says-european-commission-has-granted-orphan-drug-designation-to-temferon-for-treatment-of-glioma
Genenta Science Says European Commission H...
06/29/2023 11:03:24

genenta-reported-fy22-net-loss-of-85m-compared-to-55m-in-2021
Genenta Reported FY22 Net Loss Of €(8.5)M,...
04/26/2023 11:45:36

Genenta had a tax credit with a carrying value of €6.4 million and cash and cash equivalents of €29.8 million sufficient to all...

genenta-announces-extension-of-license-agreement-with-ospedale-san-raffaele-to-provide-access-to-all-solid-tumor-indications
Genenta Announces Extension Of License Agr...
04/03/2023 11:05:12

fda-grants-orphan-drug-designation-to-genenta-sciences-temferon-for-treatment-of-glioblastoma-multiforme
FDA Grants Orphan Drug Designation To Gene...
03/02/2023 11:46:40

Temferon is a proprietary cell therapy designed to reprogram the tumor microenvironment by delivering immunomodulatory molecule...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION